Biosimilars poised to bring savings — if they get to launch

Even as more approvals roll in and industry officials talk about how biosimilars will bring significant savings in the coming decade, there is a concern that regulatory and reimbursement hurdles could prevent the industry from realizing the full savings of the less-expensive alternative to biologics.

Want to Read More?

This content is available only to registered users. Log in to read the rest of this article or create a free account.

Login or Register to post a comment.